Skip to content

Exercise Therapy and Jaw-Mobilizing Device for Trismus in Head and Neck Cancer Patients

Exercise Therapy Combined with a Jaw-Mobilizing Device for Improving Maximal Mouth Opening and Trismus in Patients with Head and Neck Cancer: a Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06719388
Acronym
ET-JMD for Tri
Enrollment
34
Registered
2024-12-05
Start date
2021-12-01
Completion date
2024-10-31
Last updated
2024-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancers, Radiotherapy Side Effects, Trismus

Keywords

Head and Neck Cancer, Trismus, Radiotherapy-Induced Mouth Opening Limitation

Brief summary

This study evaluates the effects of exercise therapy combined with a jaw-mobilizing device on enhancing quality of life in head and neck cancer patients undergoing radiotherapy.

Detailed description

This study investigates the efficacy of exercise therapy combined with a jaw-mobilizing device (ET-JMD) in improving maximal mouth opening (MMO), preventing trismus, enhancing quality of life (QoL), and alleviating trismus-related symptoms in head and neck cancer (HNC) patients undergoing radiotherapy.

Interventions

BEHAVIORALcombination of exercise therapy and a jaw-mobilizing device

Participants in the experimental group will receive a combination of exercise therapy and a jaw-mobilizing device. The intervention includes structured exercise therapy sessions and the use of the jaw-mobilizing device for 12 weeks, beginning one week prior to radiotherapy. Follow-ups will occur at weeks 16, 24, and 36 to assess outcomes.

BEHAVIORALexercise therapy only

Participants in the control group will receive exercise therapy only. This intervention involves the same structured exercise therapy sessions as the experimental group for 12 weeks, beginning one week prior to radiotherapy. Follow-ups will occur at weeks 16, 24, and 36 to assess outcomes.

Sponsors

Taipei Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Masking description

Participants are unaware of their group allocation (experimental or control) to minimize bias in self-reported outcomes and adherence to the intervention. However, investigators and outcome assessors are not masked due to the nature of the intervention.

Intervention model description

Participants are randomly assigned to one of two parallel groups: the experimental group, which receives exercise therapy combined with a jaw-mobilizing device, or the control group, which receives exercise therapy only. Both groups are followed concurrently throughout the study period.

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 20 years. * Ability to communicate in Mandarin or Taiwanese, without significant reading, hearing, or writing impairments, and capable of completing questionnaires independently or with researcher assistance. * Diagnosed with head and neck cancer and scheduled for initial radiotherapy to the head and neck region. * Clear consciousness without severe cognitive or psychiatric disorders. * Presence of intact central incisors (#11, #41) on the right side or (#21, #31) on the left side of both the upper and lower jaws. * Baseline maximal mouth opening (MMO) ≥ 25 mm. * Willingness to participate in the study with signed informed consent.

Exclusion criteria

* Known temporomandibular joint disorders. * Postoperative wound healing complications diagnosed by a physician that prevent participation in mouth-opening rehabilitation exercises.

Design outcomes

Primary

MeasureTime frameDescription
Maximal Mouth OpeningBaseline to Week 36Change in Maximal Mouth Opening (MMO) from Baseline to Week 36. higher score means worse.

Secondary

MeasureTime frameDescription
Quality of Life ScoresBaseline to Week 36Change in Quality of Life Scores (EORTC QLQ-H&N35) from Baseline to Week 36. higher score means good quality.
Trismus-Related Symptom Distress ScoresBaseline to Week 36Change in Trismus-Related Symptom Distress Scores (GTQ2) from Baseline to Week 36. higher score means worse.

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026